Hao Yue’s patented strain

Lactobacillus fermentum GRX08

Patent No.: ZL 2013 1 0309222.7

Adjustable blood lipid levels Supports lowering blood lipids
 

1. About Blood Lipids

Each year, as many as 17 million people worldwide die from heart disease and cerebrovascular disease. Cardiovascular diseases account for approximately 30% of all global deaths annually, a figure that is projected to rise to 23 million by 2030. Cardiovascular disease is associated with multiple risk factors; studies have shown that abnormal lipid levels—particularly total cholesterol—are closely linked to the onset and progression of these conditions. Over the past few decades, cardiovascular disease has become a serious threat to human health, largely driven by dyslipidemia. vascular disease Disease has already become the leading cause of death.

Blood lipids are essential for the basal metabolism of living cells. Generally speaking, the main components of blood lipids include triglycerides, cholesterol, phospholipids, and free fatty acids. Among these, triglycerides participate in energy metabolism within the body, while cholesterol is primarily used for the synthesis of cell membranes, steroid hormones, and bile acids.

 

2. The harms of lipid abnormalities

What we commonly refer to as “high blood lipids” should actually be called “lipid abnormalities.” Among the lipid parameters, in addition to total cholesterol (TC) and triglycerides (TG),… Low-density lipoprotein cholesterol (LDL-C) An elevated level is an indicator of lipid abnormalities, and a decrease in high-density lipoprotein cholesterol (HDL-C) is also one of the signs of dyslipidemia.

For healthy lipid profiles in blood samples, lower levels of TC, TG, and LDL‑C are preferable, while higher HDL‑C is more beneficial. Epidemiological studies indicate that over 40% of adults in China have abnormal lipid levels; hyperlipidemia is a common “disease of affluence” that causes significant concern and can lead to a range of complications.
 

A wealth of research indicates that hyperlipidemia is an independent and significant risk factor for stroke, coronary heart disease, myocardial infarction, and sudden cardiac death. Moreover, it is also a major risk factor that contributes to hypertension, impaired glucose tolerance, and diabetes. Hyperlipidemia may further lead to fatty liver, liver cirrhosis, cholelithiasis, pancreatitis, retinal hemorrhage, blindness, peripheral vascular disease, claudication, and hyperuricemia, among other conditions.

How can lipid abnormalities be improved? Currently, most approaches rely on combination therapy with chemically synthesized drugs, which, when taken long-term, may cause adverse effects. Consequently, non‑pharmacological strategies for modulating lipid levels are gaining increasing attention. Recent research suggests that, in addition to regulating the host’s gut microbiota and enhancing immune function, probiotics may also help to modulate lipid metabolism to a certain extent.

 

3. The Journey of Discovering Probiotics’ Lipid-Lowering Effects

How were probiotics discovered to have the effect of lowering blood lipids?

In 1996, the University of Belgrade conducted a study involving 17 patients with non‑insulin‑dependent diabetes. Over a period of 12 weeks, the researchers administered 200 mL of fermented yogurt—containing more than one million CFU per milliliter of probiotics—to the participants three times daily. At the four‑week follow-up, serum cholesterol levels had decreased significantly by 20%, attributable to the effects of the probiotics.

 

The possible reasons are: some probiotics can absorb cholesterol and incorporate a portion of it into their bacterial cell membranes or cell walls; certain lactic acid bacteria produce… Bile salt hydrolase It can dissociate bound bile salts into free bile acids, which then form with cholesterol. Co-precipitation Moreover, free bile acids are not efficiently reabsorbed from the intestinal lumen during the enterohepatic circulation and are excreted in the feces, which promotes the conversion of cholesterol in the bloodstream into new bile acids and enhances the catabolism of cholesterol. Additionally, propionate produced by probiotic fermentation of carbohydrates can inhibit the hepatic synthesis of cholesterol and fatty acids, thereby reducing serum levels of total cholesterol and triglycerides.

 

So, does that mean all probiotics can help lower our blood lipids? The answer is no. Among the many probiotic strains, only a very small fraction possess the ability to lower blood lipids, remove cholesterol from vascular walls, and alleviate conditions such as atherosclerosis and fatty liver.

 

4grx08 Product Introduction

Lactobacillus fermentum GRX08 is a probiotic strain isolated from the gut microbiota of long-lived individuals in Rugao, exhibiting lipid‑lowering activity. It was screened through joint research conducted by Shanghai Haoyue and Yangzhou University.
 

Lactobacillus fermentum GRX08, owing to its high in vitro cholesterol‑lowering activity, robust tolerance to gastric juice, intestinal fluids, and bile salts, and strong intestinal adhesion, is widely used in fermented dairy products and dietary supplements. Next, let us explore this strain, which is hailed as the… “Lipid-Lowering Expert” patented strain – GRX08.

 

2013 application for strain preservation; preservation number: CGMCC No. 7695

In 2014, a national patent was granted, with patent number ZL 2013 1 0309222.7.

Patent Title: With Auxiliary Lipid-Lowering Function Lactobacillus fermentum grx08 and its applications

In 2019, it was transferred to Shanghai Haoyue.

 

In vitro efficacy of 5grx08

How can one develop an outstanding cholesterol‑lowering probiotic strain? A key criterion is high cholesterol‑reducing activity, coupled with strong intestinal adhesion; the strain should also exhibit robust tolerance to gastric juice, intestinal fluids, and bile salts. Lactobacillus fermentum GRX08 possesses multiple advantageous traits, including potent in vitro cholesterol‑lowering capacity, enhanced resistance to gastric acid and bile, and durable intestinal colonization—features that underpin its potential as a health‑promoting, cholesterol‑reducing probiotic.
 

The specific data are as follows:

1. In vitro cholesterol‑lowering activity: GRX08 exhibits a cholesterol degradation rate of up to 63.73%.

2. Gastric acid and bile tolerance: GRX08 exhibited a higher survival rate under pH 3.0 conditions than under pH 2.0, with rates of 68.55% and 37.01%, respectively.

3. Intestinal colonization capacity: GRX08 cells exhibit a high adhesion rate, enabling them to effectively colonize the intestinal tract and exert probiotic effects.

 

In vivo pharmacokinetic properties of 6grx08

Under various experimental studies, Lactobacillus fermentum strain GRX08 exerts significant beneficial effects on lipid profiles, promotes the degradation and elimination of cholesterol in the liver and biliary system, facilitates the synthesis and excretion of bile acids, and yields favorable findings upon histological examination of cardiac and hepatic tissues. (For more valid experimental data, please contact us.)

 

Other related research on 7grx08

1.  Study on the Lyophilization Process of GRX08 , ensuring that after freeze-drying, the lactic acid bacteria not only maintain a high viable cell count but also experience reduced physiological damage, thereby preserving their viability.

2.  Use grx08 in combination with other probiotics. , which can produce a synergistic effect and enhance the probiotic functions of the probiotics.

3 . Study on Co-Fermentation of grx08 and Streptococcus thermophilus , resulting in good water-holding capacity and moderate viscosity, Acetaldehyde content and high-quality fermented milk with a relatively high diacetyl content, while ensuring product stability throughout the shelf life.

 

[1] Li Yan, Yang Jing, Huang Yujun. Effect of Vacuum Freeze-Drying on the Fermentative Stability of Lactic Acid Bacteria [J]. Modern Food, 2017(18):72-76.

[2] Yin Boxing. Study on the Lipid-Lowering Effects and Mechanisms of Lactic Acid Bacteria-Fermented Milk [D]. Yangzhou University, 2019.

[3] Yin Boxing, Wa Yunchao, Huang Yujun, Xu Guangxin, Gu Ruixia. Study on fermentation conditions of human‑derived multi‑strain probiotics [J]. China Dairy Industry, 2019, 47(03): 4–7+16.

[4] Lu Jiacheng. Study on the Effects of Streptococcus thermophilus on the Quality of Fermented Milk Produced by Lactobacillus delbrueckii subsp. bulgaricus GRX08 [D]. Yangzhou University, 2019.

[5] Yin Boxing, Wa Yunchao, Huang Yujun, Xu Guangxin, Gu Ruixia. In vitro study on cholesterol‑lowering effects of different lactic acid bacterial strains and mixed strains [J]. Journal of Yangzhou University (Agricultural and Life Sciences Edition), 2020, 41(01): 44–49+61.

 

Food industry applications of 8grx08

Lactobacillus fermentum GRX08 bacterial powder

Viable bacterial count: 1 × 10^11 CFU/g,

Packaging specifications: 10D per bag, 1 kg per bag, or custom-made.

Storage conditions: Store at -18°C.

Case Studies of Solid Beverage Products

 

Application Cases for Plant-Based Beverages and Chocolate

 

The patented fermented Lactobacillus mucosus strain GRX08 can be incorporated into a wide range of food products, including beverages, yogurts, snacks, and dietary fibers, thereby endowing these products with more reliable functional benefits.

At present, the fermented Lactobacillus mucosus strain GRX08 has been successfully incorporated into dietary supplement products and dairy products. With… Meanwhile, we are unlocking further possibilities for Lactobacillus fermentum GRX08.

If you would like to learn more

More product information

Please contact your account manager.

We will respond to you promptly.